These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 21114432

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG, Nieminen U, Turunen U, Arkkila P, Sipponen T, Färkkilä M.
    Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
    [Abstract] [Full Text] [Related]

  • 3. Soluble urokinase plasminogen activator receptor suPAR as a marker for inflammation in pediatric inflammatory bowel disease.
    Kolho KL, Valtonen E, Rintamäki H, Savilahti E.
    Scand J Gastroenterol; 2012 Sep; 47(8-9):951-5. PubMed ID: 22746351
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
    Ricanek P, Brackmann S, Perminow G, Lyckander LG, Sponheim J, Holme O, Høie O, Rydning A, Vatn MH, IBSEN II Study Group.
    Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
    [Abstract] [Full Text] [Related]

  • 5. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA, Vernier-Massouille G, Grimaud JC, Bouhnik Y, Laharie D, Piver E, Seidel L, Colombel JF, Louis E, GETAID (Groupe d'Étude Thérapeutique Des Affections Inflammatoires Digestives).
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [Abstract] [Full Text] [Related]

  • 6. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
    Brandhorst G, Weigand S, Eberle C, Raddatz D, Karaus M, Oellerich M, Walson PD.
    Clin Chim Acta; 2013 Jun 05; 421():31-3. PubMed ID: 23485644
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial.
    Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, Rutgeerts P, Tang LK, Cornillie FJ, Sandborn WJ.
    Gut; 2014 Jan 05; 63(1):88-95. PubMed ID: 23974954
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Anti-inflammatory effect of biological treatment in patients with inflammatory bowel diseases: calprotectin and IL-6 changes do not correspond to sRAGE changes.
    Malícková K, Kalousová M, Fucíková T, Bortlík M, Duricová D, Komárek V, Zima T, Janatková I, Lukás M.
    Scand J Clin Lab Invest; 2010 Jul 05; 70(4):294-9. PubMed ID: 20446880
    [Abstract] [Full Text] [Related]

  • 14. Plasma soluble triggering receptor expressed on myeloid cells-1 in Crohn's disease.
    Billioud V, Gibot S, Massin F, Oussalah A, Chevaux JB, Williet N, Bronowicki JP, Bigard MA, Guéant JL, Peyrin-Biroulet L.
    Dig Liver Dis; 2012 Jun 05; 44(6):466-70. PubMed ID: 22341488
    [Abstract] [Full Text] [Related]

  • 15. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.
    Dig Liver Dis; 2004 May 05; 36(5):342-7. PubMed ID: 15191204
    [Abstract] [Full Text] [Related]

  • 16. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I.
    Reinisch W, Wang Y, Oddens BJ, Link R.
    Aliment Pharmacol Ther; 2012 Mar 05; 35(5):568-76. PubMed ID: 22251435
    [Abstract] [Full Text] [Related]

  • 17. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ.
    Am J Gastroenterol; 2008 Jan 05; 103(1):162-9. PubMed ID: 17916108
    [Abstract] [Full Text] [Related]

  • 18. [Application of chosen granulocyte markers in diagnostics of Leśniowski-Crohn's disease and ulcerative colitis--preliminary research].
    Fedak D, Pawlica D, Ciećko-Michalska I, Solnica B, Mach T.
    Przegl Lek; 2010 Jan 05; 67(2):114-8. PubMed ID: 20557011
    [Abstract] [Full Text] [Related]

  • 19. Assessment of capsule endoscopy scoring index, clinical disease activity, and C-reactive protein in small bowel Crohn's disease.
    Yang L, Ge ZZ, Gao YJ, Li XB, Dai J, Zhang Y, Xue HB, Zhao YJ.
    J Gastroenterol Hepatol; 2013 May 05; 28(5):829-33. PubMed ID: 23425203
    [Abstract] [Full Text] [Related]

  • 20. Assessment of the response of patients with Crohn's disease to biological therapy using new non-invasive markers: lactoferrin and calprotectin.
    Nogueira IM, Miszputen SJ, Ambrogini O, Artigiani-Neto R, Carvente CT, Zanon MI.
    Arq Gastroenterol; 2013 Apr 05; 50(2):130-7. PubMed ID: 23903623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.